Dernières nouvelles pour CVS Health (NYSE:CVS) Stock

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) shares are moving lower on Thursday after UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported earnings prior to <a href="https://www.benzinga.com//node/44860240">the market opening.</a>
What To Know: UnitedHealth reported worse-than-expected earnings today, reporting adjusted earnings per share of $7.20, missing analysts&#8217; expectations of $7.29. In addition, the insurance giant posted sales of $109.58 billion, missing analysts&#8217; expectations of $111.60 billion.
The company also cut its guidance for fiscal-year 2025 adjusted earnings per share. It now expects adjusted earnings per share of $26 to $26.50, versus analysts&#8217; estimate of $29.73. The company had previously expected adjusted earnings per share of $29.50 to $30.
UnitedHealth said the guidance change reflects higher care activity in its Medicare Advantage business and unexpected changes in Optum Health member profiles due to low engagement from beneficiaries in plans exiting certain markets.
Shares of CVS, Humana, Elevance and other health insurance companies may be trading lower after UnitedHealth reported earnings, as investors assess the health insurance industry as a whole. For instance, if UnitedHealth, the largest insurer, is missing analysts&#8217; expectations, investors may believe other companies are also facing similar challenges. The lowered guidance could also signal that UnitedHealth is feeling sustained pressure, which may weigh on the broader sector.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44863580/bitcoin-stuck-below-85000-bull-run-shakeout-or-bearish-downtrend">Bitcoin Stuck Below $85,000: Bull Run Shakeout Or Bearish Downtrend?</a>
Price Action: At the time of writing, CVS stock is trading 3.16% lower at $64.29, Humana stock is moving 7.80% lower at $260.04 and Elevance shares are trading 3.06% lower at $422.02, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: Courtesy of CVS Health Corporation

News

Movers

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

CVS, Humana and Elevance Shares Are Trading Lower Thursday: What's Going On?

WIIM

ALHC

Shares of health insurance stocks are trading lower in sympathy with UnitedHealth, which reported worse-than-expected Q1 results and cut its FY25 adjusted EPS guidance below estimates.

Baird analyst Michael Ha maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Neutral and raises the price target from $51 to $71.

Price Target

Analyst Ratings

Baird Maintains Neutral on CVS Health, Raises Price Target to $71

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $76 to $82.

Truist Securities Maintains Buy on CVS Health, Raises Price Target to $82

In the preceding three months, 8 analysts have released ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $74.12, accompanied by a high estimate of $81.00 and a low estimate of $65.00. This current average has increased by 10.63% from the previous average price target of $67.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236061_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of CVS Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $76.00&#x7C;$70.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $74.00&#x7C;$72.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $81.00&#x7C;$80.00 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $73.00&#x7C;$68.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $76.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $73.00&#x7C;$71.00 &#x7C; 
&#x7C;Michael Cherny &#x7C;Leerink Partners &#x7C;Raises &#x7C;Outperform &#x7C; $75.00&#x7C;$55.00 &#x7C; 
&#x7C;Elizabeth Anderson &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $65.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CVS Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CVS Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>Delving into CVS Health's Background</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>A Deep Dive into CVS Health's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, CVS Health showcased positive performance, achieving a revenue growth rate of 4.15% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CVS Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.18%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.65%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About CVS Health

Mizuho analyst Ann Hynes maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and raises the price target from $70 to $76.

Mizuho Maintains Outperform on CVS Health, Raises Price Target to $76

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Falls Below 5,000 Amid US-China Trade Tensions Ahead Of China Tariff Deadline, Chip Stocks Fall, Health Insurers Spike On Increased Payment Rates To Medicare Insurers

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLRY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.00</td>
<td>$609.6K</td>
<td>25.5K</td>
<td>4.0K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$65.00</td>
<td>$26.4K</td>
<td>3.7K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$105.00</td>
<td>$35.7K</td>
<td>681</td>
<td>156</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding TLRY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on January 16, 2026. Parties traded 4000 contract(s) at a $2.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $609.6K, with a price of $152.0 per contract. There were 25574 open contracts at this strike prior to today, and today 4001 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on May 16, 2025. This event was a transfer of 90 contract(s) at a $65.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $26.4K, with a price of $294.0 per contract. There were 3731 open contracts at this strike prior to today, and today 1028 contract(s) were bought and sold. 
• Regarding NVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), we observe a put option sweep with bearish sentiment. It expires in 101 day(s) on July 18, 2025. Parties traded 55 contract(s) at a $105.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $35.7K, with a price of $650.0 per contract. There were 681 open contracts at this strike prior to today, and today 156 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

TLRY

3 Health Care Stocks Whale Activity In Today's Session

U.S. stocks staged a broad-based rally on Monday, snapping a volatile losing streak after President Donald Trump hinted at a more diplomatic <a href="https://www.benzinga.com/topic/tariffs">approach to tariff negotiations.</a>
In a post on Truth Social, Trump said the U.S. is handling a "massive amount of requests for negotiations," referencing active talks with South Korea and hinting that China "wants to make a deal, badly."
He also mentioned a joint venture involving an Alaska pipeline and military cost-sharing, asserting that South Korea&#8217;s top negotiation team was en route to the U.S.
Meanwhile, Fed speakers begin to highlight the negative economic impact from tariffs. &#8220;We can&#8217;t really wait to the end of the quarter plus one month before we find out that investment really dropped off and GDP growth is shrinking,&#8221; Chicago Fed President Austan Goolsbee said.
By midday trading in New York, all major U.S. stock indices were firmly in the green. The S&amp;P 500 rose 1.4%, the Dow Jones Industrial Average gained 1.1%, and the tech-heavy Nasdaq Composite led with a 1.8% jump. Technology stocks were the day's clear outperformers, driven by a strong rebound in the semiconductor sector.
The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) surged 3.3%, marking its strongest intraday gain since September 2024. Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) led the charge with a 7.3% jump, followed by Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), which both climbed 6.1%.
In commodities, gold prices rose 0.5% to $2,335 per ounce, poised to snap a three-session losing streak. Oil prices also saw a firm recovery, with WTI crude advancing 1.5% to $61.50 per barrel, reversing recent weakness. U.S. Treasury yields remained largely flat. 
In contrast, cryptocurrency markets failed to participate in the rally. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell another 1% to $78,000. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,781.63</td>
<td>2.0%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,718.65</td>
<td>2.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,144.86</td>
<td>1.6%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,821.21</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:20 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.8% to $513.37.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rallied 2% to $387.02.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1.9% to $431.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.4% higher to 180.33.</li>
<li>The&nbsp;Financials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 2.5%; the&nbsp;Materials&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 0.1%.</li>
</ul>
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Performers</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Chg %</td>
</tr>
<tr>
<td>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)</td>
<td>9.93%</td>
</tr>
<tr>
<td>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>)</td>
<td>8.15%</td>
</tr>
<tr>
<td>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>6.48%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) </td>
<td>5.98%</td>
</tr>
<tr>
<td>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>)</td>
<td>5.77%</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">S&amp;P 500&#8217;s Worst 5 Losers</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Chg %</td>
</tr>
<tr>
<td>Albemarle Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>-8.18%</td>
</tr>
<tr>
<td>lululemon athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>)</td>
<td>-4.53%</td>
</tr>
<tr>
<td>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>)</td>
<td>-4.39%</td>
</tr>
<tr>
<td>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>)</td>
<td>-3.97%</td>
</tr>
<tr>
<td>Ralph Lauren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>)</td>
<td>-3.50%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/44696476/ups-expands-delivery-options-with-two-new-ground-services">UPS Expands Delivery Options With Two New Ground Services</a></li>
</ul>
Photo: Shutterstock

Equities

Government

Large Cap

Broad U.S. Equity ETFs

Econ #s

Federal Reserve

Tech

ETFs

$BTC

AVGO

SPDR Dow Jones Industrial Average ETF Trust

ENPH

LULU

MRVL

PLTR

SNDK

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

Select Sector SPDR-Consumer Discretionary

Stocks Rebound, Chipmakers Soar On Trade Deal Hopes, Bitcoin Lags: What's Driving Markets Tuesday?

Benzinga Market Summary: S&P Rebounds, 10-Year Rises, Health Insurers Spike On Increased Payment Rates To Medicare Insurers

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday.
Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet <a href="https://in.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Business for $2.5 billion in cash</a>.
The transaction includes Marvell&#8217;s Brightlane Automotive Ethernet portfolio and related assets. The company projected this segment to generate $225 million to $250 million in revenue in 2025, with a gross margin of around 60%.
Marvell Technology shares jumped 10.1% to $56.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 31.8% to $5.60.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) gained 23.3% to $7.38 after the company announced a 20-year LNG sale and purchase agreement to supply 1.2 million tonnes per year to a subsidiary of Saudi Aramco.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 21.4% to $8.50.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.1% to $7.36 after the company issued first-quarter preliminary revenue guidance above estimates.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) gained 16.1% to $26.60 after HC Wainwright &amp; Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) jumped 14.9% to $20.48.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 14.7% to $3.9098.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) climbed 14.6% to $192.29.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) rose 14% to $12.81.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) gained 14% to $1.14 after the company announced it increased its share repurchase program by $20 million to $40 million.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 12.3% to $286.14 following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 12.4% to $61.76. Canaccord Genuity analyst Whitney Ijem maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $81 to $92.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) rose 12.4% to $3.9150.</li>
<li>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) gained 12.4% to $35.40.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose 10% to $34.26.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 10% to $255.36.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 8.5% to $69.29 after the company announced changes to management and Medicare increased advantage payment rates.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 7.9% to $105.39.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) rose 7.8% to $85.05.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 6.3% to $248.09.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 4.2% to $189.13. U.S. consumers are reportedly rushing to Apple stores to purchase new iPhones ahead of potential price hikes caused by President Donald Trump&#8217;s newly announced tariffs on Chinese imports.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44682968/how-to-earn-500-a-month-from-delta-air-lines-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Trading Ideas

AAOI

AAPL

CRMD

CVNA

GRAB

NVDA

PCRX

RYTM

SHOP

TSLA

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

U.S. stocks surged in early trading Tuesday after President Donald Trump hinted at progress on some trade deals with key trading partners, easing fears of global trade disruption stemming <a href="https://www.benzinga.com/topic/tariffs">from recent tariff announcements.</a>
The S&amp;P 500 index, as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), surged 3% by 9:45 a.m. in New York, clawing back some of the 10% it had lost over the previous four sessions.
Other major indices also showed robust gains, with the tech-heavy Nasdaq 100 – tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – outperforming counterparts amid broad-based rallies in mega-cap and semiconductor stocks.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
<td>%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,025.43</td>
<td>+594.75</td>
<td>3.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,121.15</td>
<td>+1,155.55</td>
<td>3.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,213.82</td>
<td>+151.57</td>
<td>3.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,858.95</td>
<td>+48.84</td>
<td>2.7%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 9:45 a.m. ET</figcaption></figure>
After suffering steep losses in recent sessions, investors poured back into financials, tech, and consumer discretionary, which were the top-performing sectors on Tuesday. 
Semiconductors were the standout industry group, with the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) rallying 4.5%.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>S&amp;P Sector ETFs</td>
<td>%</td>
</tr>
<tr>
<td>Financial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>4.0%</td>
</tr>
<tr>
<td>Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>3.8%</td>
</tr>
<tr>
<td>Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>3.0%</td>
</tr>
<tr>
<td>Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>2.9%</td>
</tr>
<tr>
<td>Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>2.7%</td>
</tr>
<tr>
<td>Industrials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>2.7%</td>
</tr>
<tr>
<td>Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>1.8%</td>
</tr>
<tr>
<td>Real Estate&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>1.4%</td>
</tr>
<tr>
<td>Materials&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>1.4%</td>
</tr>
<tr>
<td>Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>1.3%</td>
</tr>
<tr>
<td>Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>1.2%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Trump Sparks Optimism With Trade Talk Blitz</h3>
The catalyst behind the rally was a lengthy post on Truth Social by Trump, in which he described a "great call" with South Korea's acting president. 
The president said South Korea is sending a "top team" to the U.S. for negotiations, calling the process &#8220;one-stop shopping&#8221; for trade and military agreements.
In a <a href="https://edition.cnn.com/2025/04/08/asia/south-korea-acting-president-han-interview-intl-hnk/index.html">CNN</a> interview, South Korea&#8217;s acting president confirmed the country would not align with China and Japan to counter U.S. tariffs. 
Seoul faces 25% tariffs under Trump's global tariff rollout. Instead, it aims to strike a bilateral agreement with the U.S. to avoid a blow to its export-driven economy.
Trump also hinted at more openness in trade negotiations with China after threatening Monday to impose a 50% tariff on top of the 54% already levied.
&#8220;China also wants to make a deal, badly, but they don&#8217;t know how to get it started,&#8221; Trump wrote.
&#8220;We are waiting for their [China's] call. It will happen!&#8221; he added, suggesting renewed momentum on U.S.-China trade talks.
Senior White House economic adviser Kevin Hassett echoed the optimism, telling Fox News that the Trump administration is focusing on countries with "large trade deficits" with the U.S. He emphasized that "fair and reciprocal trade" remains the administration&#8217;s goal.
<h3 class="wp-block-heading">Mega-cap stocks (S&amp;P 100): Top 7 performers</h3>
Among S&amp;P 100 companies, CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) led gains with a 9.26% surge, followed by Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Last</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health Corp. </td>
<td>69.76</td>
<td>+9.26%</td>
</tr>
<tr>
<td>Broadcom Inc.</td>
<td>168.07</td>
<td>+9.04%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. </td>
<td>563.81</td>
<td>+7.45%</td>
</tr>
<tr>
<td>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>104.71</td>
<td>+7.24%</td>
</tr>
<tr>
<td>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</td>
<td>545.01</td>
<td>+5.57%</td>
</tr>
<tr>
<td>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</td>
<td>246.28</td>
<td>+5.57%</td>
</tr>
<tr>
<td>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</td>
<td>226.30</td>
<td>+5.53%</td>
</tr>
</tbody>
</table>
</figure>
The biggest market-moving headline of the session was the explosive increase in market capitalization among the Magnificent Seven — Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Meta Platforms Inc., Tesla Inc., and NVIDIA Corp. — which collectively added over $564 billion in market value.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>Market Cap gain</td>
</tr>
<tr>
<td>NVIDIA</td>
<td>$165.82 B</td>
</tr>
<tr>
<td>Apple</td>
<td>$92.40 B</td>
</tr>
<tr>
<td>Microsoft</td>
<td>$85.39 B</td>
</tr>
<tr>
<td>Amazon</td>
<td>$70.02 B</td>
</tr>
<tr>
<td>Meta Platforms </td>
<td>$67.36 B</td>
</tr>
<tr>
<td>Alphabet (Google)</td>
<td>$48.48 B</td>
</tr>
<tr>
<td>Tesla</td>
<td>$35.19 B</td>
</tr>
</tbody>
<tfoot>
<tr>
<td>Total Market Cap Gain </td>
<td> $564.66 billion</td>
</tr>
</tfoot>
</table>
</figure>
<h3 class="wp-block-heading">Nasdaq 100: Standout Performers</h3>
AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) was the top gainer in the Nasdaq 100, soaring 10.62%, while Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) followed with strong moves.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Last</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>AppLovin Corp. </td>
<td>256.89</td>
<td>+10.62%</td>
</tr>
<tr>
<td>Marvell Technology Inc. </td>
<td>55.76</td>
<td>+9.34%</td>
</tr>
<tr>
<td>Broadcom Inc. </td>
<td>168.19</td>
<td>+9.12%</td>
</tr>
<tr>
<td>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>)</td>
<td>84.79</td>
<td>+8.93%</td>
</tr>
<tr>
<td>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>)</td>
<td>95.91</td>
<td>+8.21%</td>
</tr>
<tr>
<td>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>104.65</td>
<td>+7.18%</td>
</tr>
<tr>
<td>MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>)</td>
<td>1,921.14</td>
<td>+7.04%</td>
</tr>
</tbody>
</table>
</figure>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/44685614/treasury-secretary-bessent-says-china-holds-losing-hand-in-tariff-escalation">Treasury Secretary Bessent Says China Holds &#8216;Losing Hand&#8217; In Tariff Escalation</a></li>
</ul>
Image created using photos from Shutterstock.

AMZN

GOOGL

MELI

MSFT

XLRE

Wall Street Soars As Trump Teases Trade Deals, Magnificent 7 Add Over $500 Billion In Market Value

CVS Health shares are trading higher after the company announced changes to management and Medicare increased advantage payment rates.

CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) on Tuesday named Brian Newman as executive vice president and chief financial officer designate, effective&nbsp;April 21.
He will succeed current chief financial officer Tom&nbsp;Cowhey, who will transition as a strategic advisor to president and chief executive officer&nbsp;David Joyner, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44680644/cvs-health-announces-chief-financial-officer-transition-plan-appoints-chief-medical-officer" rel="noreferrer noopener">effective&nbsp;May 12</a>.
Newman was most recently executive vice president and chief financial officer of United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth's PBMs Amid Commissioner Shortage</a>
Before joining UPS, Newman spent 26 years with PepsiCo, where he held finance leadership roles across&nbsp;Europe,&nbsp;Asia, and North and&nbsp;South America. He also served as executive vice president for PepsiCo's global operations and chief strategy officer. Newman began his career as an investment banker at PaineWebber.
Amy Compton-Phillips, the company's new executive vice president and chief medical officer, effective&nbsp;May 19, will also report to David&nbsp;Joyner.
Dr. Compton-Phillips was most recently chief physician executive of Press Ganey, a health care performance improvement company.
Prior to Press Ganey, Dr. Compton-Phillips was the president and chief clinical officer at Providence Health &amp; Services, a health care system, responsible for clinical operations and care including improving health, care, and value outcomes delivered by the system's hospitals, clinics, and caregivers. From 1985 to 2007, she held positions of increasing responsibility at Kaiser Permanente.
In February, CVS Health reported fourth-quarter sales of $97.71 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43709040/cvs-health-gains-momentum-after-q4-performance-analyst-upgrades-stock" rel="noreferrer noopener">consensus of $97.19 billion</a>.
Total revenues increased 4.2%, driven by growth in the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments, partially offset by a decline in the&nbsp;Health Services segment.
The Medical benefit ratio increased from 88.5% to 94.8% compared to the prior year, driven by increased utilization, the unfavorable impact of the previously disclosed decline in the company's Medicare Advantage star ratings for the 2024 payment year, and the impact of higher acuity in Medicaid.
In October 2024, CVS Health&nbsp;appointed longtime executive&nbsp;David Joyner as its new president and CEO, replacing&nbsp;Karen Lynch amid the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">ongoing financial struggles</a>.
In November 2024, CVS&nbsp;Health appointed Prem&nbsp;Shah as the Group President, responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company's&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769048/cvs-health-announces-leadership-appointments" rel="noreferrer noopener">Healthcare Delivery businesses</a>.
In addition, the company appointed Steve Nelson&nbsp;as President of Aetna.
Price Action: At the last check on Tuesday, CVS stock was up 9.52% at $69.93 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/forex/25/04/44680574/global-markets-rebound-in-relief-rally-gold-back-to-3000" target="_blank" rel="noreferrer noopener">Global Markets Rebound In Relief Rally, Gold Back To $3,000</a></li>
</ul>
Photo via Shutterstock

Health Care

Management

CVS Health Appoints Former UPS And Pepsi Exec As Finance Chief, Stock Soars

Shares of health insurers are trading higher following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.

<a href="https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure" title="https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure">https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure</a>

Insider Trades

Bloomberg Reported Monday, CVS Health Is Facing Activist Investor

Guidance

CVS Expects Financial Results To Meet Or Exceed FY25 Guidance

CVS Health Names Brian Newman As Executive Vice President And Chief Financial Officer Designate Effective April 21

Health insurer stocks are trading higher after the market close on Monday following a report indicating the Trump administration will increase payment rates <a href="https://www.benzinga.com/topic/medicare">for Medicare insurers</a>.
What Happened: The Centers for Medicare and Medicaid Services (CMS) announced Monday that it will increase payment rates for Medicare insurers to 5.06%. The rate is well above the 2.23% proposed by the Biden administration and above all prior analyst expectations, according to the <a href="https://www.wsj.com/health/healthcare/private-medicare-plans-to-get-big-payment-boost-from-trump-administration-017d9aaa">Wall Street Journal</a>.
The report indicates that investors are expected to view the increase as a show of support from the Trump administration for Medicare Advantage, under which private companies can offer Medicare-approved insurance plans. 
&#8220;By finalizing these payment policies, CMS is ensuring that Medicare Advantage continues to offer access to critical services in an efficient, accountable manner, further strengthening the program's ability to serve beneficiaries,&#8221; the Medicare agency <a href="https://www.cms.gov/newsroom/press-releases/cms-finalizes-2026-payment-policy-updates-medicare-advantage-and-part-d-programs">said</a> in a press release.
The new head of CMS Mehmet Oz has long been a supporter of private insurance plans in Medicare, according to the Wall Street Journal. CMS reportedly said the payment rate increase reflects higher medical costs. 
&#8220;The actions taken by CMS help protect beneficiaries and taxpayers from waste, fraud, and abuse, while also driving access to high-quality, affordable healthcare through Medicare Advantage,&#8221; CMS said.
Here&#8217;s a look at some of the health insurer stocks making big moves following the announcement:
<ul>
<li>CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) up 6.50% at $68</li>
</ul>
<ul>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) up 5.77% at $555</li>
</ul>
<ul>
<li>Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 12.08% at $285.49</li>
</ul>
<ul>
<li>Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) up 6.35% at $450</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44669062/top-3-health-care-stocks-that-may-crash-in-q2">Top 3 Health Care Stocks That May Crash In Q2</a></li>
</ul>
Photo: Shutterstock.

After-Hours Center

Health Insurers Surge After Medicare Agency Increases Payment Rates

Despite Wall Street continuing to tumble at the start of the second quarter of 2025, a small group of S&amp;P 500 stocks has remained nearly untouched by the chaos triggered by <a href="https://www.benzinga.com/topic/tariffs">Donald Trump's tariff policies.</a>
Stocks that delivered standout gains in the first quarter have held their ground through the opening week of the second quarter, showing resilience as the broader market sank under pressure from tariffs and softening earnings outlooks.
The five best-performing S&amp;P 500 names in Q1 2025 — CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) — have seen only minimal declines in recent days, defying a sharp 10% drop in the S&amp;P 500 index fueled by mounting trade tensions and concerns over recession. 
<h3 class="wp-block-heading">Quarterly Stars In A Cloudy Market</h3>
Let's break it down:
<ul>
<li>CVS Health soared 50.9% in Q1, posting its best quarterly gain since 1975. While the S&amp;P 500 dropped 10% in the first week of April, CVS is only down 5% in Q2.</li>
<li>Philip Morris jumped 31.9% last quarter, reaching multiple record highs and logging its second-best quarter since going public in 2008. PM is down 4.8% thus far in April.</li>
<li>Newmont rode the gold wave. With gold prices up 19%, the mining giant surged 29.7%, its strongest 3-month performance since early 2020. NEM fell 7.2% in Q2, yet showed a more contained drop than the broader market.</li>
<li>Cencora, formerly AmerisourceBergen, posted a 23.8% rise, and remains up 0.2% this month, dodging the tariff-driven downturn.</li>
<li>Vertex Pharmaceuticals climbed 21% in Q1, and has stayed flat so far in Q2, showing impressive stability in biotech.</li>
</ul>
<h3 class="wp-block-heading">But How Much More Room To Run?</h3>
Despite their impressive runs, future gains may be limited. Analyst consensus shows only Newmont and CVS have potential upside of 25.8% and 13.2%, respectively, based on median price targets. 
For the others, the path forward looks far less compelling. With valuations already stretched and macroeconomic risks mounting — from renewed trade tensions to signs of weakening corporate margins — the potential for further gains could quickly evaporate if analysts begin slashing forecasts in the coming weeks.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Q1 2025 Price Change</th>
<th>YTD Price Change</th>
<th>Median Target Upside</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health (CVS)</td>
<td>+50.9%</td>
<td>+43.71%</td>
<td>+13.16%</td>
</tr>
<tr>
<td>Philip Morris (PM)</td>
<td>+31.9%</td>
<td>+26.02%</td>
<td>+2.86%</td>
</tr>
<tr>
<td>Newmont Corporation (NEM)</td>
<td>+29.7%</td>
<td>+21.77%</td>
<td>+25.77%</td>
</tr>
<tr>
<td>Cencora Inc. (COR)</td>
<td>+23.8%</td>
<td>+23.78%</td>
<td>+0.68%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals (VRTX)</td>
<td>+21.0%</td>
<td>+19.20%</td>
<td>+6.66%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of April 7, 2025</figcaption></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">Emergency Fed Rate Cut Odds Spike As Trump Says &#8216;No Inflation,&#8217; Calls for Immediate Action</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Education

VRTX

These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue?

Earnings

Press Releases

CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2024 RESULTS

Ed DeVaney named President of CVS Caremark

Thermo Fisher Scientific Elects New Director to Board

CVS Pharmacy® introduces enhanced flu testing and treatment offerings

Wellvana acquires CVS Health's MSSP business

CVS Health Foundation helps address barriers to care and provides resources for individuals with chronic health conditions in Hartford

CVS Weight Management™ Program Improves Health Outcomes While Also Lowering Costs

Dividends

CVS Health declares quarterly dividend

CVS Health to hold first quarter 2025 earnings conference call

CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

CVS Health

Actualités

Dernières nouvelles pour CVS Health (NYSE:CVS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL